DNA methyltransferase expression (DNMT1, DNMT3a and DNMT3b) as a potential biomarker for anti-VEGF diabetic macular edema response
Open Access
- 20 April 2023
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 33 (6) , 2267-2274
Abstract
Purpose: DNA methylation is involved in Diabetic Retinopathy progression showing a metabolic memory mechanism. However, the association of DNA methyltransferase with diabetic macular edema is still unknown. We aimed to describe the differences in DNA methyltransferase gene expression in patients with different diabetic macular edema responses. Methods: A total of 27 diabetic patients, aged 59–90 years, were prospectively enrolled in this cross-sectional study. The participants were classified into control group (CG, n = 11), diabetic macular edema responders (rDME, n = 9) and non-responder diabetic macular edema (nrDME, n = 7) after anti-vascular endothelial growth factor (anti-VEGF) treatment. Only cases with a complete ophthalmological examination, digital 133° color fundus, and SD-OCT assessments were used. After RNA extraction and first-strand cDNA synthesis, quantitative real-time PCR was performed with specific primers on the CFX Connect™ Real-Time PCR Detection System to assess differential transcriptional expression patterns. Results: The DNMT1 gene showed a positive correlation (r = 0.617; p = 0.043) with Best Corrected Visual Acuity (BCVA) in CG, a positive correlation (r = 0.917; p = 0.010) with HbA1c in nrDME and a negative correlation (r = −0.659; p = 0.049) with GCL-IPL thickness in rDME. DNMT3A gene showed a positive correlation (r = −0.890; p = 0.001) with Sub-foveal Choroidal thickness in rDME whereas DNMT3b gene showed a negative correlation (r = −0.815; p = 0.007) with HbA1c and RNFL (r = −0.664; p = 0.026) in CG. Conclusions: Patients with similar metabolic profile risk factors showed associated DNA methyltransferase transcriptional expression patterns differences fitting with the anti-VEGF diabetic macular edema response. Further studies are needed to clarify if these results (1) reflect disease evolution, (2) translate the therapeutic impact, (3) or can help to predict the therapeutic resistance profile.Keywords
Funding Information
- Instituto Politécnico de Lisboa (IDI&CA grant IPL/2021/DiffMeDiME_ESTeSL)
This publication has 42 references indexed in Scilit:
- Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I DataAmerican Journal of Ophthalmology, 2016
- Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet, 2016
- Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathyBMC Medicine, 2015
- Epigenetic Modification of Mitochondrial DNA in the Development of Diabetic RetinopathyInvestigative Ophthalmology & Visual Science, 2015
- An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight lossGenome Biology, 2015
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD StatementBMC Medicine, 2015
- Global DNA methylation as a possible biomarker for diabetic retinopathyDiabetes/Metabolism Research and Reviews, 2014
- Differential systemic gene expression profile in patients with diabetic macular edema: Responders versus nonresponders to standard treatmentIndian Journal Of Ophthalmology, 2014
- Epigenetic Modifications and Diabetic RetinopathyBioMed Research International, 2013
- Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretionDiabetologia, 2008